About us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients’ biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting.

The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The Senzime AB (publ) share are listed on NASDAQ Stockholm First North. Short name: SEZI.

Press releases

Comparative Investigation of TetraGraph and TOF-Watch SX

Read more

Senzime submits 510 (k) application to the FDA

Read more

Senzime signs distribution agreement for the Swiss market

Read more
See all »

News

Meet Senzime at Medica Trade Fair in Düsseldorf, 13-16 November

Read more

Senzime reports from the American Society of Anesthesiologists (ASA)

Read more

NEWS: Senzime reports from the Innovation Pavilion at The MedTech Conference

Read more
See all »